Principal Investigator: Amir Arain
Keywords: Adjunctive Therapy in Adults with Drug-Resistant Focal Onset Seizures. Department: Neurology
IRB Number: 00130130
Specialty: Neurology
Sub Specialties: EEG
Recruitment Status: Recruiting

Contact Information

Liz Diaz
liz.diaz@utah.edu
8015814819

Brief Summary

  • To evaluate the efficacy of CVL-865 as adjunctive therapy compared with placebo in subjects with focal onset seizures
  • To evaluate the safety and tolerability of CVL-865 in subjects with focal onset seizures
  • To evaluate the plasma exposure of CVL-865

Inclusion Criteria

1. Male and female subjects, ages 18 to 75 years, inclusive, at the time of signing the ICF.

2. A diagnosis of epilepsy with focal onset (as defined in the 2017 ILAE Classification of Seizures [Fisher et al, 2017]), focal aware (except subjects with only focal aware seizures without a motor component), focal impaired awareness, and focal to bilateral tonic-clonic seizures for at least 2 years prior to signing the ICF. Diagnosis will be based on the investigator’s assessment of available clinical, radiographic, and EEG data and the review by TESC.

3. A history of an average of 4 or more spontaneous and observable focal onset (as defined in

the 2017 ILAE Classification of Seizures [Fisher et al, 2017]), focal aware (except subjects with only focal aware seizures without a motor component), focal impaired awareness, and focal to bilateral tonic-clonic seizures per 28-day period for at least 3 months (84 days) prior to signing the ICF.

4. A minimum of 8 focal onset (as defined in the 2017 ILAE Classification of Seizures [Fisher et

al, 2017]), focal aware (except subjects with only focal aware seizures without a motor component), focal impaired awareness, or focal to bilateral tonic-clonic seizures during the 8-

week Baseline Period with no 21-day period free of any of these seizure types.

5. Subjects who have tried and failed at least 2 appropriate AEDs in the past.

6. Subjects currently taking 1 to 3 permitted AEDs (see concomitant medication exclusions) at a

stable dose for 4 weeks prior to the Screening Visit. VNS, DBS, and RNS is permitted and is not considered an AED. The VNS, DBS, and RNS settings should remain stable for 4 weeks prior to the Screening Visit. Note: Should a subject require a change of AED therapy/dose or VNS, DBS, or RNS settings between the Screening Visit and Visit 1, that subject should not continue in the trial at that time but must remain on the new regime for at least 4 weeks and then may repeat the screening process.

7. An MRI or CT scan of the head within 10 years prior to Screening Visit to demonstrate no

progressive structural abnormality. If a scan is not available, one should be conducted during

the Baseline Period with a report that demonstrated no progressive structural abnormality

available prior to randomization.

8. BMI of 17.5 to 40.0 kg/m2 and a total body weight >50 kg (110 lbs).

9. A female subject of childbearing potential (see Section 10.4, Appendix 4) who is sexually

active with a nonsterilized male partner must agree to use a highly effective method of contraception (see Section 10.4, Appendix 4) from signing of informed consent throughout

the duration of the study and for 30 days post last dose.

A male subject with a pregnant or a nonpregnant partner of childbearing potential must agree

to use condom during treatment and until the end of relevant systemic exposure in the male

subject for 94 days following the last dose with IMP.

10. Capable of giving signed informed consent as described in Section 10.1.3 (Appendix 1),

which includes compliance with the requirements and restrictions listed in the ICF and in this

protocol.

11. Ability, in the opinion of the investigator, to understand the nature of the trial and comply

with protocol requirements, including the prescribed dosage regimens, scheduled visits, laboratory tests, and other trial procedures.

Exclusion Criteria

Target Disease

1. Subjects with (genetic) idiopathic generalized epilepsies or combined generalized and focal

epilepsies, including a history of Lennox-Gastaut Syndrome.

2. Subjects with only focal aware seizures without a motor component.

3. Subjects with a history of seizures over the past 12 months that occur at such a high frequency

they cannot be counted (eg, repetitive seizures, cluster seizures).

4. Subjects with a history of psychogenic non-epileptic seizures within the year prior to signing

the ICF.

5. Subjects with a history of status epilepticus within 5 years prior to signing the ICF.

6. Subjects with a history of neurosurgery for seizures less than 1 year prior to signing the ICF,

or radiosurgery less than 2 years prior to signing the ICF.

 

Medical History and Concurrent Diseases

7. Subjects with a current history of significant cardiovascular, pulmonary, gastrointestinal,

renal, hepatic, metabolic, hematological, immunological, or neurological (excluding focal

onset epilepsy) disease that, in the opinion of the investigator or medical monitor, could

compromise either subject safety or the results of the trial. In addition, subjects with a

psychiatric illness of sufficient severity as to make them inappropriate for the trial are

excluded.

 

Medical conditions that are minor or well-controlled may be considered acceptable if the condition does not expose the subject to an undue risk of a significant AE or interfere with the

assessments of safety or efficacy during the course of the trial. The medical monitor should be

contacted in any instance where the investigator is uncertain regarding the stability of a subject’s medical conditions(s) and the potential impact of the condition(s) on trial participation.

8. Subjects with an active CNS infection, demyelinating disease, degenerative neurological

disease or any CNS disease deemed to be progressive during the course of the trial that may

confound the interpretation of the trial results.

9. Subjects with a history of substance or alcohol-use disorder (excluding nicotine; DSM-5

criteria) within 2 years prior to signing the ICF.

10. Subjects who answer “Yes” on the C-SSRS Suicidal Ideation Item 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) and whose most recent episode meeting

criteria for this C-SSRS Item 4 occurred within the last 6 months, OR Subjects who answer “Yes” on the C-SSRS Suicidal Ideation Item 5 (Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting criteria for this CSSRS Item 5 occurred within the last 6 months OR Subjects who answer “Yes” on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years, OR Subjects who, in the opinion of the investigator, present a serious risk of suicide.

 

Physical Examination and Clinical Laboratory Results

11. Subjects with human immunodeficiency virus seropositive status or acquired immunodeficiency syndrome, chronic hepatitis B or C (defined as positive serology and AST

or ALT elevated to >2 × ULN).

12. Subject with a positive drug screen for illicit drugs are excluded and may not be retested or

rescreened. Subjects with a positive urine drug screen resulting from use of marijuana (any

cannabinoids), prescription, or over the counter medications or products that, in the investigator’s documented opinion do not signal a clinical condition that would impact the

safety of the subject or interpretation of the trial results may continue evaluation for the trial

following consultation and approval by the medical monitor.

13. Subjects with a 12-lead ECG demonstrating either of the following:

• QT interval corrected for heart rate using Fridericia’s formula (QTcF) >450 msec (average of 3 ECGs obtained at the Screening Visit assessed by central reader)

• QRS interval >120 msec at the Screening Visit

14. Subjects with any of the following abnormalities in clinical laboratory tests at the Screening

Visit, as assessed by the central laboratory and confirmed by a single repeat measurement, if

deemed necessary:

  • AST or ALT ≥2 × ULN
  • Total bilirubin ≥1.5 × ULN. Subjects with a history of Gilbert’s syndrome may be eligible provided the direct (conjugated) bilirubin is <ULN
  • Females: Hemoglobin <11 g/dL; Males: hemoglobin <12 g/dL
  • White blood cell (WBC) count <3.0 × 10^9/L
  • Neutrophil count <2.0 × 10^9/L
  • Platelet count <150 × 10^9/L

15. Subjects with other abnormal laboratory test results, vital sign results, or ECG findings unless, based on the investigator’s judgment, the findings are not medically significant and would not impact the safety of the subjects or the interpretation of the trial results. The medical monitor should be contacted to discuss individual cases, as needed.

 

Tests with exclusionary results should be repeated to ensure reproducibility of the

abnormality before excluding a subject based on criteria provided in this protocol. For ECGs,

3 consecutive recordings are required and if 2 of the 3 remain exclusionary, then the subject is

not eligible for the trial.

 

Disallowed Prior and Concomitant Medications

16. Subjects receiving more than 3 background AEDs for their epilepsy.

17. Subjects taking BZD medication chronically or who require a BZD (oral, intramuscular, or

suppository) as rescue medication for epilepsy for more than 4 days on average over a 28-day

period. (Note: a rescue BZD will be permitted if used ≤4 days on average over a 28-day

period). During the Screening/Baseline Period, subjects requiring a BZD (oral, intramuscular,

or suppository) as rescue medication for epilepsy more than 4 days on average over a 28-day

period will be excluded.

18. Subjects taking other prohibited medications prior tp randomization (as listed in Table 6) or who would be likely to require the use of prohibited concomitant medications during the trial (as is listed in Table 7).

19. Subjects taking any drug that is strong or moderate inducer/inhibitor CYP3A4 metabolism,

which has the potential to alter CVL-865 exposure levels (see Section 6.5).

20. Subjects taking any drug that is a sensitive P-gp and BCRP substrate (see Section 6.5).

21. Vigabatrin is excluded as a concomitant AED, unless subject has been taking it for at least 2

years prior to signing the ICF and have no evidence of visual field defects on at least 2 visual

field tests within 6 months of signing the ICF.

22. Felbamate is excluded as a concomitant AED, unless subject has been taking it for at least 2

years prior to signing the ICF, with a stable dose for ≥49 days, and have acceptable hematology and liver function test values (or discontinued felbamate no less than 49 days prior to signing the ICF).

 

Other

23. Female subjects who are breastfeeding and/or who have a positive pregnancy test result prior

to receiving IMP.

24. Any condition possibly affecting drug absorption, including bowel resections, bariatric weight loss surgery, or gastrectomy (this does not include gastric banding).

25. Subjects with difficulty swallowing.

26. Subjects who are known to be allergic or hypersensitive to the IMP or any of its components.

27. Subjects who have participated in any clinical trial within 60 days prior to signing the ICF or

who have participated in more than 2 clinical trials within the year prior to signing the ICF.

28. Any subject who, in the opinion of the sponsor, investigator, or medical monitor, should